Clinical study on Two Ayurveda medicines Arogyavardhini Vati and Kumaryasava in non-alcoholic fatty liver disease (Yakrit Vikar)

An open label single arm clinical evaluation of Arogyavardhini Vati with Kumaryasava in the management of Yakriddalyudara (non alcoholic fatty liver disease) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094793

Enrollment

Registered

2025-09-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: K759- Inflammatory liver disease, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Grade I and II fatty liver Elevated SGOT, SGPT, ALP Newly diagnosed or treated NAFLD cases Controlled diabetes with fatty liver Willingness to participate and consent

Exclusion criteria

Exclusion criteria: Hepatitis B,C, autoimmune, drug-induced hepatitis, alcoholic liver disease Serious systemic illnesses Grade III fatty liver Pregnancy/lactation

Design outcomes

Primary

Measure	Time frame
Improvement in USG grading of fatty liver after 60 days Changes in LFT parameters (SGOT, SGPT, ALP, GGT etc.) Timepoint: First follow-up 4 weeks Second follow-up 8 weeks	—

Secondary

Measure	Time frame
Reduction in symptoms such as weakness, anorexia, indigestion, abdominal pain,constipation, vomiting, mild fever, fatigue, excessive thirstTimepoint: Baseline, 30thday, 60th day	—

Countries

India

Contacts

Public ContactDr Girish KJ

PATANJALI BHARTIYA AYURVIGYAN EVAM ANUSANDHAN SANSTHAN HARIDWAR

girideepa@yahoo.co.in9448646855

Outcome results